Form 4: Janux Therapeutics CEO Awarded Stock Options and Restricted Stock Units

Janux Therapeutics CEO, David Alan Campbell, received stock options and restricted stock units as part of his compensation package.

Summary

• David Alan Campbell, the President and CEO of Janux Therapeutics, was granted 81,000 restricted stock units (RSUs) and 283,500 stock options on January 2, 2025.
• The RSUs vest in four equal annual installments starting January 1, 2026.
• 25% of the stock options vest on January 1, 2026, with the remaining balance vesting monthly over the following three years.
• The stock options have an exercise price of $53.24.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options and RSUs aligns the CEO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

This type of equity compensation is common for executives in publicly traded companies, particularly in the biotech sector, to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option and RSU grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead, and Regeneron also use similar equity-based incentives to attract and retain top talent.
• The vesting schedules are typical, with a mix of cliff vesting and monthly vesting over a period of years.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align the CEO's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, Janux Therapeutics, insider trading, form 4, vesting